Pharmaceuticals Company Announces Confirmation Study Approval For Type 1 Diabetes Treatment
Biodexa Pharmaceuticals Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada.
Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, recently announced the initiation of a Phase 2a dose confirmation study of Tolimidone for the treatment of Type 1 Diabetes (T1D). This study has been approved by Health Canada and will be conducted as an Investigator Initiated Trial (IIT) by the University of Alberta. The forthcoming clinical trial will evaluate the efficacy and safety of Tolimidone, a drug initially developed by Pfizer Inc. for gastric ulcers but later repurposed for potential use in T1D due to promising preclinical results. $Biodexa Pharmaceuticals (BDRX.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment